{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:03:50Z","timestamp":1783613030712,"version":"3.55.0"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["23ZR1412400"],"award-info":[{"award-number":["23ZR1412400"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anlotinib, a multitarget tyrosine kinase inhibitor, can inhibit tumour angiogenesis proliferation, metastasis, promote vascular normalization, increase T cell and NK cell activity and infiltration, remodel tumour microenvironment and synergistic immune enhancement. <jats:italic>Our study aimes<\/jats:italic> to evaluate the efficacy of anlotinib in the treatment of advanced metastatic breast cancer (MBC) after multiple lines of therapy. Patients <jats:italic>included were<\/jats:italic> treated with anlotinib for advanced MBC in the Affiliated Cancer Hospital of Zhengzhou University from 1 January 2019 to 30 June <jats:italic>2023.<\/jats:italic> The objective remission rate, disease\u2010free <jats:italic>progression<\/jats:italic> survival and adverse reactions were analysed. We compared and analysed the efficacy of anlotinib in the treatment of advanced metastatic breast cancer, which showed that ORR was 23.6% and DCR was 69.1%. The DCR of monotherapy was 66.7% and that of combination therapy was 69.6% in MBC patients. The combination therapy, combined with chemotherapy had the best effect (79.3%), combined with immunotherapy came second. In addition, the DCR (88.9%) was higher in MBC patients having received prior antiangiogenic therapy. According to the Kaplan\u2013Meier (K\u2010M) survival estimate analysis, the mPFS was 4.17\u2009months (95% CI, 1.758\u20136.582\u2009months) in Her\u20102 positive MBC patients, and 7.83\u2009months (95% CI, 2.416\u20139.104) in Her\u20102 negative MBC patients. The mPFS was 5.76\u2009months (95% CI, 3.231\u20138.298\u2009m) in HR positive MBC patients, 7.83\u2009months (95% CI, 3.182\u201312.478\u2009m) in TNBC patients. Fatigue (20.0%), hypertension (21.8%) and liver dysfunction (18.2%) were common adverse reactions, followed by bone marrow suppression (16.4%), anorexia (14.5%), hypothyroidism (14.5%) and diarrhoea (14.5%). Altogether, Anlotinib monotherapy or combination therapy provides a viable third (or above)\u2010line therapeutic strategy in patients with metastatic breast cancer. The adverse reactions of anlotinib are well tolerated and controllable.<\/jats:p>","DOI":"10.1111\/jcmm.18008","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:50:04Z","timestamp":1698465004000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study"],"prefix":"10.1111","volume":"28","author":[{"given":"Shuochuan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Breast disease, Henan Breast Cancer Center The Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital  Zhengzhou Henan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Zhi","sequence":"additional","affiliation":[{"name":"Deprtment of Ultrasonography, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1438-8586","authenticated-orcid":false,"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Combine Traditional Chinese &amp; Western The Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital  Zhengzhou Henan Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03190-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab279"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"issue":"3","key":"e_1_2_10_5_1","first-page":"212","article-title":"Analysis of the epidemic situation of malignant tumors in China in 2016","volume":"45","author":"Zheng R","year":"2023","journal-title":"Chin J Oncol"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34838-w"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010038"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11462"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.07.014"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.02.026"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2704125"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937924"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092272"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky062"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21778"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2944"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5021"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1140-x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1456599"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S178395"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2018.01.003"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00775"},{"key":"e_1_2_10_24_1","unstructured":"ESMO.Metastatic Breast Cancer Living Guideline. V1.12023."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.942767"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00205-4"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.939343"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100409"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01052-9"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13878"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0640"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5479491"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01256-2"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2511-3"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02641-5"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02421-w"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2049232"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0463"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1042451"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcmm.18008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T07:57:07Z","timestamp":1712390227000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcmm.18008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/jcmm.18008"],"URL":"https:\/\/doi.org\/10.1111\/jcmm.18008","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"value":"1582-1838","type":"print"},{"value":"1582-4934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"2023-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e18008"}}